PMID- 30004271
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220413
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 33
IP  - 2
DP  - 2020 Apr
TI  - Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in 
      a Large Urban Hospital.
PG  - 136-141
LID - 10.1177/0897190018788264 [doi]
AB  - OBJECTIVE: The aim of this study is to assess patterns of potential drug-drug 
      interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient 
      hospital setting. METHODS: A retrospective chart review was conducted at the 
      Brookdale University Hospital and Medical Center (BUHMC) from January 2014 to 
      November 2016. All adult patients admitted to the BUHMC who were treated with a 
      DOAC for at least 3 days were screened. Among them, those who received selected 
      interacting drugs at any time during the course of DOAC therapy were included in 
      this study. RESULTS: This study included 165 patients with an average of 73 years 
      (standard deviation [SD] = 12.3) and 233 cases. The most commonly used 
      concomitant drug with a DOAC was aspirin (58%), followed by amiodarone (16%) and 
      P2Y(12) inhibitors (11%). The combined use of dual antiplatelet therapy and a 
      DOAC was identified in 18 (6%) cases. Approximately one-third of the cases 
      encountered were classified as the "avoidance" category. CONCLUSIONS: Despite 
      computerized DDI alerts, potentially significant DDIs with DOACs still occur. 
      While the present study provides insight into the current patterns of DDIs, 
      further studies are needed to evaluate clinical outcomes of the potential DDIs 
      with DOACs in practice.
FAU - Mo, Yoonsun
AU  - Mo Y
AD  - Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island 
      University Pharmacy, Brooklyn, NY, USA.
FAU - Karakas-Torgut, Ayse
AU  - Karakas-Torgut A
AD  - Brookdale University Hospital and Medical Center, Brooklyn, NY, USA.
FAU - Pham, Antony Q
AU  - Pham AQ
AD  - Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island 
      University Pharmacy, Brooklyn, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20180713
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Pyridones)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin
MH  - Dabigatran/administration & dosage
MH  - Drug Combinations
MH  - *Drug Interactions
MH  - Drug-Related Side Effects and Adverse Reactions/*drug therapy
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Hospitals, Urban
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyridones/administration & dosage
MH  - Retrospective Studies
MH  - Rivaroxaban/administration & dosage
OTO - NOTNLM
OT  - anticoagulant agents
OT  - apixaban
OT  - dabigatran
OT  - drug interaction
OT  - rivaroxaban
EDAT- 2018/07/14 06:00
MHDA- 2021/01/05 06:00
CRDT- 2018/07/14 06:00
PHST- 2018/07/14 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2018/07/14 06:00 [entrez]
AID - 10.1177/0897190018788264 [doi]
PST - ppublish
SO  - J Pharm Pract. 2020 Apr;33(2):136-141. doi: 10.1177/0897190018788264. Epub 2018 
      Jul 13.